A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Leu JH, Miao X, Shalayda K, Coe KJ, Kahnt A, Wu B, Schnarr M, Franks C, Devlin J, Yang TY, Palmer JA, Zhang M, Zhou H, Van Damme W, Smets S, Aguilar Z, Chaplan SR.
Leu JH, et al. Among authors: schnarr m.
Clin Pharmacol Drug Dev. 2023 Jun;12(6):611-624. doi: 10.1002/cpdd.1253. Epub 2023 May 1.
Clin Pharmacol Drug Dev. 2023.
PMID: 37125450
Clinical Trial.